NCT04938232 2026-02-05Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHLDana-Farber Cancer InstitutePhase 2 Active not recruiting13 enrolled 19 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled